Mirum and Incyte Zilurgisertib Approval: What It Means for Biotech ETFs

The regulatory green light for zilurgisertib represents a pivotal development for both Mirum Pharmaceuticals and Incyte, as the companies prepare to navigate the commercialization phase for this rare bone disorder treatment. For investors tracking the broader…